NKTXNkarta, Inc.
- GlobeNewswire
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, ...
- GlobeNewswire
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
Initial clinical data for NKX019 in idiopathic inflammatory myopathy (myositis) and systemic sclerosis (scleroderma) to be presented at ACR Convergence 2026 Cash balance of $216.0 million on September 30, 2026, ...
- Analyst Upgrades
HC Wainwright & Co. Assumes Nkarta at Buy, Announces Price Target of $12
HC Wainwright & Co. analyst Douglas Tsao assumes Nkarta with a Buy rating and announces Price Target of $12. ...
- Earnings Call Transcripts
NKARTA, INC. STIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - NKARTA INC
All right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stiefel. And apologies for the late start. We're trying to get Nadir patched in, but he is available through Paul's phon ...
- Earnings Call Transcripts
STIFEL 2026 VIRTUAL IMMUNOLOGY AND INFLAMMATION FORUM - NKARTA INC
All right. Good afternoon, everyone. I'm Stephen Willey, one of the senior biotech analysts here at Stiefel. And apologies for the late start. We're trying to get Nadir patched in, but he is available through Paul's phon ...
- GlobeNewswire
Nkarta to Participate in September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune ...
- GlobeNewswire
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Two abstracts selected for oral presentations, highlighting investigational CAR-NK cell therapy’s clinical activity in idiopathic inflammatory myopathy and overall safety profile Third abstract selected for poster ...
- Analyst Upgrades
Stifel Maintains Buy on Nkarta, Lowers Price Target to $10
Stifel analyst Stephen Willey maintains Nkarta with a Buy and lowers the price target from $11 to $10. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $14
HC Wainwright & Co. analyst Emily Bodnar maintains Nkarta with a Buy and lowers the price target from $16 to $14. ...
- GlobeNewswire
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle)Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a ...
- GlobeNewswire
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Alyssa Levin appointed to Board of Directors and as Chair of the Audit CommitteeClara Cambon-Thiebaud joins as VP, Regulatory AffairsCéline Breda ...
- PR Newswire
A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital ... ...
- GlobeNewswire
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune ...
- GlobeNewswire
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell
Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for ...
- GlobeNewswire
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet
Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while ...
- PR Newswire
The $13 Million Company Teaching the Immune System to Hunt Cancer
USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)... ...
- PR Newswire
Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first ... ...
- Analyst Upgrades
Needham Reiterates Buy on Nkarta, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Nkarta with a Buy and maintains $11 price target. ...
- GlobeNewswire
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient ...
- GlobeNewswire
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Expanded treatment in community settings will reduce patient burdenOption to redose patients granted in both Ntrust-1 and Ntrust-2 studiesRheumatoid arthritis cohort to be added to Ntrust-2Dosing continues at 4 billion ...
- GlobeNewswire
Nkarta to Participate in Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune ...
- Analyst Upgrades
Mizuho Maintains Outperform on Nkarta, Lowers Price Target to $12
Mizuho analyst Salim Syed maintains Nkarta with a Outperform and lowers the price target from $14 to $12. ...
- Analyst Upgrades
Needham Maintains Buy on Nkarta, Raises Price Target to $11
Needham analyst Gil Blum maintains Nkarta with a Buy and raises the price target from $10 to $11. ...
- GlobeNewswire
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycleInitial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical ...
- GlobeNewswire
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune ...